Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial

El Saghir, Nagi S.; Yap, Yoon Sim; Eralp, Yesim; Im, Seock\\-Ah; Azim, Hamdy A.; Rihani, Julie; Volkov, Nikita; Chen, Shin\\-Cheh; Harputluoglu, Hakan; Sunpaweravong, Patrapim; Chang, Yuan\\-Ching; Delgar Alfaro, Teresa; Wu, Jiwen; Hu, Huilin; Gao, Ming; Lu, Yen\\-Shen

doi:10.1200/JCO.2023.41.16\_suppl.1063

Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial

Date

2023

Authors

Sunpaweravong, Patrapim

dc.identifier.doi

10.1200/JCO.2023.41.16\_suppl.1063

dc.identifier.other

WOS:001555395200010

Publisher

LIPPINCOTT WILLIAMS \& WILKINS

DOI

10.1200/JCO.2023.41.16\_suppl.1063

URI

https://openaccess.acibadem.edu.tr/handle/11443/6417

Collections

WOS

Full item page

Outcomes with first-line (1L) ribociclib (RIB) plus endocrine therapy (ET) vs physician's choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2-advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial

Date

Authors

Journal Title

Journal ISSN

Volume Title

dc.identifier.issn

dc.identifier.doi

dc.identifier.other

dc.description.volume

dc.description.issue

Publisher

DOI

Abstract

Description

Keywords

Citation

URI

Collections

Endorsement

Review

Supplemented By

Referenced By